Literature DB >> 7471618

Kinetic equivalence of stable-isotope-labeled and unlabeled phenytoin.

T R Browne, A Van Langenhove, C E Costello, K Biemann, D J Greenblatt.   

Abstract

Stable isotope labeling (SIL) of a drug results in a higher molecular weight than that of the unlabeled drug. SIL tracer doses can be quantitated separately from unlabeled drug by gas chromatography-mass spectrometry (GC-MS) without exposing the patient to radiation. The higher molecular weight of SIL drug could cause a higher energy of activation for (and slowing of) metabolic reactions ("isotope effect"). To evaluate possible isotope effect, three dogs and three men were infused with a mixture containing equal amounts of SIL (2-13C-1,3-15N2) and unlabeled phenytoin (PHT). Plasma and urine were collected at regular intervals. Concentrations of SIL and unlabeled PHT and HPPH (the major metabolite of PHT) were determined by GC-MS. Within each subject there was no trend for concentrations of SIL PHT or HPPH to be higher or lower than concentrations of their unlabeled analogs (greater than 0.20 to 0.90). There was no difference in the distribution and elimination half-lifes (t 1/2s), volume of distribution, volume of central compartment, or clearance of the two forms of PHT. Thus, no isotope effect was found.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7471618     DOI: 10.1038/clpt.1981.71

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

Review 1.  Stable isotopes in clinical pharmacokinetic investigations. Advantages and disadvantages.

Authors:  T R Browne
Journal:  Clin Pharmacokinet       Date:  1990-06       Impact factor: 6.447

2.  Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism.

Authors:  G M Rubin; J A Waschek; S M Pond; D J Effeney; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

Review 3.  Application of stable labelled drugs in clinical pharmacokinetic investigations.

Authors:  M Eichelbaum; G E von Unruh; A Somogyi
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

4.  Viable Staphylococcus aureus quantitation using ¹⁵N metabolically labeled bacteriophage amplification coupled with a multiple reaction monitoring proteomic workflow.

Authors:  Carrie L Pierce; Jon C Rees; Facundo M Fernández; John R Barr
Journal:  Mol Cell Proteomics       Date:  2011-10-04       Impact factor: 5.911

5.  Mass spectrometry-based quantitative proteomic analysis of Salmonella enterica serovar Enteritidis protein expression upon exposure to hydrogen peroxide.

Authors:  Kihoon Kim; Edward Yang; Gia-Phong Vu; Hao Gong; Jing Su; Fenyong Liu; Sangwei Lu
Journal:  BMC Microbiol       Date:  2010-06-08       Impact factor: 3.605

6.  The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin.

Authors:  R G Dickinson; W D Hooper; B Wood; C M Lander; M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.